Mitochondrial dysfunction in schizophrenia: Pathways, mechanisms and implications

Neuroscience and Biobehavioral Reviews

Volumn 48, Issue , 2015, Pages 10-21

  Rajasekaran, Ashwini ^a   Venkatasubramanian, Ganesan ^a   Berk, Michael ^b,c   Debnath, Monojit ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH AND NEUROSCIENCES   (India)

^b DEAKIN UNIVERSITY   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Inflammation; Mitochondria; Neuroprogression; Oxidative stress; Schizophrenia

Indexed keywords

ACETYLCYSTEINE; CALCIUM; CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; REACTIVE OXYGEN METABOLITE;

APOPTOSIS; BIOENERGY; CALCIUM HOMEOSTASIS; CELL DEATH; CELL FUNCTION; DISEASE SEVERITY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ENERGY METABOLISM; GENOMICS; HUMAN; IMAGE ANALYSIS; NERVE CELL DIFFERENTIATION; NERVOUS SYSTEM INFLAMMATION; NEUROBIOLOGY; NEUROLOGIC DISEASE; NITROSATIVE STRESS; OXIDATION REDUCTION STATE; OXIDATIVE STRESS; PATHOGENESIS; PROTEOMICS; RESPIRATORY CHAIN; REVIEW; SCHIZOPHRENIA; ANIMAL; BRAIN; DRUG EFFECTS; GENETICS; GROWTH, DEVELOPMENT AND AGING; MITOCHONDRION; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; BRAIN; HUMANS; MITOCHONDRIA; SCHIZOPHRENIA;

EID: 84913553786     PISSN: 01497634     EISSN: 18737528     Source Type: Journal    
DOI: 10.1016/j.neubiorev.2014.11.005     Document Type: Review

References (193)

1. Al-Asmari A.K., Khan M.W. Inflammation and schizophrenia: alterations in cytokine levels and perturbation in antioxidative defense systems. Hum. Exp. Toxicol. 2014, 33(2):115-122.
2. Altar C.A., Jurata L.W., Charles V., Lemire A., Liu P., Bukhman Y., Brockman J.A. Deficient hippocampal neuron expression of proteasome, ubiquitin, and mitochondrial genes in multiple schizophrenia cohorts. Biol. Psychiatry 2005, 58(2):85-96.
3. Altunkaynak B.Z., Ozbek E., Unal B., Aydin N., Aydin M.D., Vuraler O. Chronic treatment of haloperidol induces pathological changes in striatal neurons of guinea pigs: a light and electron microscopical study?. Drug Chem. Toxicol. 2012, 35(4):406-411.
4. Amar S., Shamir A., Ovadia O., Blanaru M., Reshef A., Kremer I., Mishmar D. Mitochondrial DNA HV lineage increases the susceptibility to schizophrenia among Israeli Arabs. Schizophr. Res. 2007, 94(1-3):354-358.
5. Anderson G., Berk M., Dodd S., Bechter K., Altamura A.C., Dell'osso B., Kanba S., Monji A., Fatemi S.H., Buckley P., Debnath M., Das U.N., Meyer U., Müller N., Kanchanatawan B., Maes M. Immuno-inflammatory, oxidative and nitrosative stress, and neuroprogressive pathways in the etiology, course and treatment of schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 2013, 42:1-4.
6. Anderson G., Maes M., Berk M. Schizophrenia is primed for an increased expression of depression through activation of immuno-inflammatory, oxidative and nitrosative stress, and tryptophan catabolite pathways. Prog. Neuropsychopharmacol. Biol. Psychiatry 2013, 42:101-114.
7. Andreazza A.C., Shao L., Wang J.F., Young L.T. Mitochondrial complex I activity and oxidative damage to mitochondrial proteins in the prefrontal cortex of patients with bipolar disorder. Arch. Gen. Psychiatry 2010, 67:360-368.
8. Anglin R.E., Garside S.L., Tarnopolsky M.A., Mazurek M.F., Rosebush P.I. The psychiatric manifestations of mitochondrial disorders: a case and review of the literature. J. Clin. Psychiatry 2012, 73(4):506-512.
9. Antonenko Y.N., Rokitskaya T.I., Cooper A.J., Krasnikov B.F. Minocycline chelates Ca2+, binds to membranes, and depolarizes mitochondria by formation of Ca2+-dependention channels. J. Bioenerg. Biomembr. 2010, 42(2):151-163.
10. Atkin T.A., MacAskill A.F., Brandon N.J., Kittler J.T. Disrupted in Schizophrenia-1 regulates intracellular trafficking of mitochondria in neurons. Mol. Psychiatry 2011, 16(2):122-128.
11. Bauer M., Praschak-Rieder N., Kasper S., Willeit M. Is dopamine neurotransmission altered in prodromal schizophrenia? A review of the evidence. Curr. Pharm. Des. 2012, 18:1568-1579.
12. Ben-Shachar D., Zuk R., Gazawi H., Reshef A., Sheinkman A., Klein E. Increased mitochondrial complex I activity in platelets of schizophrenic patients. Int. J. Neuropsychopharmacol. 1999, 2:245-253.
13. Ben-Shachar D. Mitochondrial dysfunction in schizophrenia: a possible linkage to dopamine. J. Neurochem. 2002, 83(6):1241-1251.
14. Ben-Shachar D., Zuk R., Gazawi H., Ljubuncic P. Dopamine toxicity involves mitochondrial complex I inhibition: implications to dopamine-related neuropsychiatric disorders?. Biochem. Pharmacol. 2004, 67(10):1965-1974.
15. Ben-Shachar D., Karry R. Sp1 expression is disrupted in schizophrenia; a possible mechanism for the abnormal expression of mitochondrial complex I genes, NDUFV1 and NDUFV2. PLoS One 2007, 2(9):e817.
16. Berk M., Plein H., Belsham B. The specificity of platelet glutamate receptor supersensitivity in psychotic disorders?. Life Sci. 2000, 66(25):2427-2432.
17. Berk M., Copolov D., Dean O., Lu K., Jeavons S., Schapkaitz I., Anderson-Hunt M., Judd F., Katz F., Katz P., Ording-Jespersen S., Little J., Conus P., Cuenod M., Do K.Q., Bush A.I. N-acetyl cysteine as a glutathione precursor for schizophrenia-a double-blind, randomized, placebo-controlled trial. Biol. Psychiatry 2008, 64:361-368.
18. Berk M., Williams L.J., Jacka F.N., O'Neil A., Pasco J.A., Moylan S., Allen N.B., Stuart A.L., Hayley A.C., Byrne M.L., Maes M. So depression is an inflammatory disease, but where does the inflammation come from?. BMC Med. 2013, 11:200.
19. Berk M., Malhi G.S., Gray L.J., Dean O.M. The promise of N-acetylcysteine in neuropsychiatry. Trends Pharmacol. Sci. 2013, 34:167-177.
20. Bertholet A.M., Millet A.M., Guillermin O., Daloyau M., Davezac N., Miquel M.C., Belenguer P. OPA1 loss of function affects in vitro neuronal maturation. Brain 2013, 136(Pt. 5):1518-1533.
21. Billups B., Forsythe I.D. Presynaptic mitochondrial calcium sequestration influences transmission at mammalian central synapses. J. Neurosci. 2002, 22(14):5840-5847.
22. Bitanihirwe B.K.Y., Woo T.U.W. Oxidative stress in schizophrenia: an integrated approach. Neurosci. Biobehav. Rev. 2011, 35(3):878-893.
23. Blass P. Glucose/Mitochondria in neurological conditions. Int. Rev. Neurobiol. 2002, 51:325-376.
24. Block M.L., Hong J.S. Microglia and inflammation-mediated neurodegeneration: multiple triggers with a common mechanism. Prog. Neurobiol. 2005, 76(2):77-98.
25. Bloom F.E. Advancing a neurodevelopmental origin for schizophrenia?. Arch. Gen. Psychiatry 1993, 50(3):224-227.
26. Boskovic M., Vovk T., Kores Plesnicar B., Grabnar I. Oxidative stress in Schizophrenia. Curr. Neuropharmacol. 2011, 9(2):301-312.
27. Brenner-Lavie H., Klein E., Zuk R., Gazawi H., Ljubuncic P., Ben-Shachar D. Dopamine modulates mitochondrial function in viable SH-SY5Y cells possibly via its interaction with complex I: relevance to dopamine pathology in schizophrenia?. Biochim. Biophys. Acta 2008, 1777(2):173-185.
28. Brinton R.D. Estrogen regulation of glucose metabolism and mitochondrial function: therapeutic implications for prevention of Alzheimer's disease. Adv. Drug Delivery Rev. 2008, 60(13-14):1504-1511.
29. Brisch R., Saniotis A., Wolf R., Bielau H., Bernstein H.G., Steiner J., Bogerts B., Braun A.K., Jankowski Z., Kumaritlake J., Henneberg M., Gos T. The role of dopamine in schizophrenia from a neurobiological and evolutionary perspective: old fashioned, but still in vogue. Front. Psychiatry 2014, 19(5):47.
30. Brown A.S. Exposure to prenatal infection and risk of schizophrenia. Front. Psychiatry 2011, 2:63.
31. Casademont J., et al. Neuroleptic treatment effect on mitochondrial electron transport chain: peripheral blood mononuclear cells analysis in psychotic patients. J. Clin. Psychopharmacol. 2007, 27:284-288.
32. Cavelier L., Jazin E., Eriksson I., Prince J., Bave U., Oreland L., et al. Decreased cytochrome c oxidase activity and lack of age related accumulation of mtDNA in brain of schizophrenics. Genomics 1995, 29:217-228.
33. Chang K.C., Hsu C.C., Liu S.H., Su C.C., Yen C.C., Lee M.J., Chen K.L., Ho T.J., Hung D.Z., Wu C.C., Lu T.H., Su Y.C., Chen Y.W., Huang C.F. Cadmium induces apoptosis in pancreatic β-cells through a mitochondria-dependent pathway: the role of oxidative stress-mediated c-Jun N-terminal kinase activation. PLoS One 2013, 8(2):e54374.
34. Chaturvedi R.K., Flint Beal M. Mitochondrial diseases of the brain. Free Radical Biol. Med. 2013, 63:1-29.
35. Chaudhry I.B., Hallak J., Husain N., et al. Minocycline benefits negative symptoms in early schizophrenia: a randomised double-blind placebo-controlled clinical trial in patients on standard treatment. J. Psychopharmacol. 2012, 26:1185-1193.
36. Chen C.H., Chen S.J., Su C.C., Yen C.C., Tseng T.J., Jinn T.R., Tang F.C., Chen K.L., Su Y.C., Lee K.I., Hung D.Z., Huang C.F. Chloroacetic acid induced neuronal cells death through oxidative stress-mediated p38-MAPK activation pathway regulated mitochondria-dependent apoptotic signals. Toxicology 2013, 303:72-82.
37. Chen H., Detmer S.A., Ewald A.J., Griffin E.E., Fraser S.E., Chan D.C. Mitofusins Mfn1 and Mfn2 co-ordinately regulate mitochondrial fusion and are essential for embryonic development. J. Cell Biol. 2003, 160(2):189-200. 20.
38. Cheng A., Hou Y., Mattson M.P. Mitochondria and neuroplasticity. ASN Neuro 2010, 2(5):e00045.
39. Chowdari K.W., Bamne M.N., Nimgaonkar V.L. Genetic association studies of antioxidant pathway genes and schizophrenia. Antioxid. Redox Signaling 2011, 15:2037-2045.
40. Contreras-Shannon V., Heart D.L., Paredes R.M., Navaira E., Catano G., Maffi S.K., Walss-Bass C. Clozapine-induced mitochondria alterations and inflammation in brain and insulin-responsive cells. PLoS One 2013, 8(3):e59012.
41. Csernansky J.G. Neurodegeneration in schizophrenia: evidence from in vivo neuroimaging studies. Sci. World J. 2007, 2(7):135-143.
42. Davis J., Moylan S., Harvey B.H., Maes M., Berk M. Neuroprogression in schizophrenia: pathways underpinning clinical staging and therapeutic corollaries. Aust. N.Z. J. Psychiatry 2014, 48(6):512-529.
43. de Oliveira L., Fraga D.B., De Luca R.D., Canever L., Ghedim F.V., Matos M.P., Streck E.L., Quevedo J., Zugno A.I. Behavioral changes and mitochondrial dysfunction in a rat model of schizophrenia induced by ketamine. Metab. Brain Dis. 2011, 26(1):69-77.
44. Debnath M., Doyle K.M., Langan C., McDonald C., Leonard B., Cannon D.M. Recent advances in psychoneuroimmunology: inflammation in psychiatric disorder. Transl. Neurosci. 2011, 2:121-137.
45. Debnath M., Berk M. Th17 pathway-mediated immunopathogenesis of schizophrenia: mechanisms and implications. Schizophr Bull. 2014, 40(6):1412-1421.
46. DeLisi L.E. The concept of progressive brain change in schizophrenia: implications for understanding schizophrenia. Schizophr. Bull. 2008, 34:312-321.
47. Do K.Q., Cabungcal J.H., Frank A., Steullet P., Cuenod M. Redox dysregulation, neurodevelopment, and schizophrenia. Curr. Opin. Neurobiol. 2009, 19:220-230.
48. Dror N., Klein E., Karry R., Sheinkman A., Kirsh Z., Mazor M., Tzukerman M., Ben-Shachar D. State-dependent alterations in mitochondrial complex I activity in platelets: a potential peripheral marker for schizophrenia?. Mol. Psychiatry 2002, 7(9):995-1001.
49. Duan X., Chang J.H., Ge S., Faulkner R.L., Kim J.Y., Kitabatake Y., Song H. Disrupted-In-Schizophrenia 1 regulates integration of newly generated neurons in the adult brain. Cell 2007, 130(6):1146-1158.
50. Duchen M.R. Mitochondria in health and disease: perspectives on a new mitochondrial biology. Mol. Aspects Med. 2004, 25:365-451.
51. Elkashef A.M., Al-Barazi H., Venable D., Baker I., Hill J., Apud J., Wyatt R.J. Dopamine effect on the mitochondria potential in B lymphocytes of schizophrenic patients and normal controls?. Prog. Neuropsychopharmacol. Biol. Psychiatry 2002, 26(1):145-148.
52. Eykelenboom J.E., Briggs G.J., Bradshaw N.J., Soares D.C., Ogawa F., Christie S., et al. A t(1;11) translocation linked to schizophrenia and affective disorders gives rise to aberrant chimeric DISC1 transcripts that encode structurally altered, deleterious mitochondrial proteins. Hum. Mol. Genet. 2012, 21(15):3374-3386.
53. Faizi M., Salimi A., Rasoulzadeh M., Naserzadeh P., Pourahmad J. Schizophrenia induces oxidative stress and cytochrome C release in isolated rat brain mitochondria: a possible pathway for induction of apoptosis and neurodegeneration. Iran J. Pharm. Res. 2014, 13(Suppl):93-100.
54. Faludi G., Mirnics K. Synaptic changes in the brain of subjects with schizophrenia. Int. J. Dev. Neurosci. 2011, 29(3):305-309.
55. Farokhnia M., Azarkolah A., Adinehfar F., Khodaie-Ardakani M.R., Hosseini S.M., Yekehtaz H., Tabrizi M., Rezaei F., Salehi B., Sadeghi S.M., Moghadam M., Gharibi F., Mirshafiee O., Akhondzadeh S. N-acetylcysteine as an adjunct to risperidone for treatment of negative symptoms in patients with chronic schizophrenia: a randomized, double-blind, placebo-controlled study. Clin. Neuropharmacol. 2013, 36:185-192.
56. Fernandez-Egea E., Bernardo M., Heaphy C.M., Griffith J.K., Parellada E., Esmatjes E., Conget I., Nguyen L., George V., Stöppler H., Kirkpatrick B. Telomere length and pulse pressure in newly diagnosed, antipsychotic-naive patients with nonaffective psychosis. Schizophr. Bull. 2009, 35:437-442.
57. Flyckt L., Edman G., Venizelos N., Borg K. Aberrant tyrosine transport across the fibroblast membrane in patients with schizophrenia-indications of maternal inheritance?. J. Psychiatr. Res. 2011, 45(4):519-525.
58. Fuke S., Kametani M., Kato T. Quantitative analysis of the 4977-bp common deletion of mitochondrial DNA in postmortem frontal cortex from patients with bipolar disorder and schizophrenia. Neurosci. Lett. 2008, 439:173-177.
59. Gibson G.E., Starkov A., Blass J.P., Ratan R.R., Beal M.F. Cause and consequence: mitochondrial dysfunction initiates and propagates neuronal dysfunction, neuronal death and behavioral abnormalities in age-associated neurodegenerative diseases. Biochim. Biophys. Acta 2010, 1802(1):122-134.
60. Giulivi C., Napoli E., Schwartzer J., Careaga M., Ashwood P. Gestational exposure to a viral mimetic poly(i:c) results in long-lasting changes in mitochondrial function by leucocytes in the adult offspring. Mediators Inflamm. 2013, 609602:8.
61. Goldstein J.M., Faraone S.V., Chen W.J., Tolomiczencko G.S., Tsuang M.T. Sex differences in the familial transmission of schizophrenia. Br. J. Psychiatry 1990, 156:819-826.
62. Gonçalves V.F., Zai C.C., Tiwari A.K., Brandl E.J., Derkach A., Meltzer H.Y., et al. A hypothesis-driven association study of 28 nuclear-encoded mitochondrial genes with antipsychotic-induced weight gain in schizophrenia. Neuropsychopharmacology 2014, 39:1347-1354.
63. Gubert C., Stertz L., Pfaffenseller B., Panizzutti B.S., Rezin G.T., Massuda R., et al. Mitochondrial activity and oxidative stress markers in peripheral blood mononuclear cells of patients with bipolar disorder, schizophrenia, and healthy subjects. J. Psychiatr. Res. 2013, 47(10):1396-1402.
64. Hagberg H., Mallard C., Rousset C.I., Thronton C. Mitochondria: hub of injury responses in the developing brain. Lancet Neurol. 2014, 13(2):217-232.
65. Halim N.D., Lipska B.K., Hyde T.M., Deep-Soboslay A., Saylor E.M., Herman M.M., Thakar J., Verma A., Kleinman J.E. Increased lactate levels and reduced pH in postmortem brains of schizophrenics: medication confounds. J. Neurosci. Methods 2008, 169:208-213.
66. Halliwell B. Reactive species and antioxidants. redox biology is a fundamental theme of aerobic life. Plant Physiol. 2006, 141:312-322.
67. Harrison P.J., Weinberger D.R. Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. Mol. Psychiatry 2005, 10:40-68.
68. Hastings T.G., Zigmond M.J. Identification of catechol-protein conjugates in neostriatal slices incubated with [3H] dopamine: impact of ascorbic acid and glutathione. J. Neurochem. 1994, 63:1126-1132.
69. Howes O.D., Kapur S. The dopamine hypothesis of schizophrenia: Version III-The final common pathway. Schizophr. Bull. 2009, 35(3):549-562.
70. Hudson G., Gomez-Duran A., Wilson I.J., Chinnery P.F. Recent mitochondrial DNA mutations increase the risk of developing common late-onset human diseases. PLoS Genet. 2014, 10(5):e1004369.
71. Hulshoff Pol H.E., Kahn R.S. What happens after the first episode? A review of progressive brain changes in chronically ill patients with schizophrenia. Schizophr. Bull. 2008, 34:354-366.
72. Ichikawa T., Arai M., Miyashita M., Arai M., Obata N., Nohara I., Oshima K., Niizato K., Okazaki Y., Doi N., Itokawa M. Schizophrenia: maternal inheritance and heteroplasmy of mtDNA mutations?. Mol. Genet. Metab. 2012, 105(1):103-109.
73. Ikebe S., Tanaka M., Ozawa T. Point mutations of the mitochondrial genome in Parkinson's disease. Mol. Brain Res. 1995, 28:281-295.
74. Insel T.R. Rethinking schizophrenia. Nature 2010, 468(7321):187-193.
75. Inuwa I.M., Peet M., Williams M.A. QSAR modeling and transmission electron microscopy stereology of altered mitochondrial ultrastructure of white blood cells in patients diagnosed as schizophrenic and treated with antipsychotic drugs. Biotech. Histochem. 2005, 80:133-137.
76. Ishihara N., Nomura M., Jofuku A., Kato H., Suzuki S.O., Masuda K., et al. Mitochondrial fission factor Drp1 is essential for embryonic development and synapse formation in mice. Nat. Cell Biol. 2009, 11:958-966.
77. Iwamoto K., Bundo M., Kato T. Altered expression of mitochondria-related genes in postmortem brains of patients with bipolar disorder or schizophrenia, as revealed by large-scale DNA microarray analysis. Hum. Mol. Genet. 2005, 14(2):241-253.
78. Jablensky A., Angelicheva D., Donohoe G.J., Cruickshank M., Azmanov D.N., Morris D.W., et al. Promoter polymorphisms in two overlapping 6p25 genes implicate mitochondrial proteins in cognitive deficit in schizophrenia. Mol. Psychiatry 2012, 17(12):1328-1339.
79. James R., Adams R.R., Christie S., Buchanan S.R., Porteous D.J., Millar J.K. Disrupted in Schizophrenia 1 (DISC1) is a multicompartmentalized protein that predominantly localizes to mitochondria. Mol. Cell. Neurosci. 2004, 26:112-122.
80. Jiang Z., Cowell R.M., Nakazawa K. Convergence of genetic and environmental factors on parvalbumin-positive interneurons in schizophrenia. Front. Behav. Neurosci. 2013, 3(7):116.
81. Jousse C., Muranishi Y., Parry L., Montaurier C., Even P., Launay J.M., et al. Perinatal protein malnutrition affects mitochondrial function in adult and results in a resistance to high fat diet-induced obesity. PLoS One 2014, 13(9(8)):e104896.
82. Junn E., Mouradian M.M. Apoptotic signaling in dopamine-induced cell death: the role of oxidative stress, p38 mitogen activated protein kinase, cytochrome c and caspases. J. Neurochem. 2001, 78(2):374-383.
83. Kann O., Kovacs R. Mitochondria and neuronal activity. Am. J. Physiol. Cell Physiol. 2007, 292:C641-C657.
84. Karry R., Klein E., Ben Shachar D. Mitochondrial complex I subunits expression is altered in schizophrenia: a postmortem study. Biol. Psychiatry 2004, 55(7):676-684.
85. Karachitos A., García Del Pozo J.S., de Groot P.W., Kmita H., Jordán J. Minocycline mediated mitochondrial cytoprotection: premises for therapy of cerebrovascular and neurodegenerative diseases?. Curr. Drug Targets 2013, 14(1):47-55.
86. Kato A., Suzuki K., Kaneta H., Obara H., Fujishima Y., Sato S. Regional differences in cerebral glucose metabolism in cirrhotic patients with subclinical hepatic encephalopathy using positron emission tomography. Hepatol. Res. 2000, 17(3):237-245.
87. Kelly D.L., Vyas G., Richardson C.M., et al. Adjunct minocycline to clozapine treated patients with persistent schizophrenia symptoms. Schizophr. Res. 2011, 133:257-258.
88. Kirkpatrick B., Miller B.J. Inflammation and schizophrenia. Schizophr. Bull. 2013, 39:1174-1179.
89. Kogelnik A.M., Lott M.T., Brown M.D., Navathe S.B., Wallace D.C. MITOMAP: a human mitochondrial genome database. Nucleic Acids Res. 1996, 24:177-179.
90. Kolomeets N.S., Uranova N. Ultrastructural abnormalities of astrocytes in the hippocampus in schizophrenia and duration of illness: a postortem morphometric study. World J. Biol. Psychiatry 2010, 11(2):282-292.
91. Kulkarni J., Gavrilidis E., Wang W., Worsley R., Fitzgerald P.B., Gurvich C., Van Rheenen T., Berk M., Burger H. Estradiol for treatment-resistant schizophrenia: a large-scale randomized-controlled trial in women of child-bearing age. Mol. Psychiatr. 2014, 15(Apr). 10.1038/mp.2014.33.
92. Kung L., Roberts R.C. Mitochondrial pathology in human schizophrenic striatum: a postmortem. Synapse 1999, 31:67-75.
93. Kvajo M., Dhilla A., Swor D.E., Karayiorgou M., Gogos J.A. Evidence implicating the candidate schizophrenia/bipolar disorder susceptibility gene G72 in mitochondrial function. Mol. Psychiatry 2008, 13(7):685-696.
94. Lante F., Meunier J., Guiramand J., Maurice T., Cavalier M., de Jesus Ferreira M.C., Aimar R., Cohen-Solal C., Vignes M., Barbanel G. Neurodevelopmental damage after prenatal infection: role of oxidative stress in the fetal brain. Free Radical Biol. Med. 2007, 42:1231-1245.
95. Leung A.W., Halestrap A.P. Recent progress in elucidating the molecular mechanism of the mitochondrial permeability transition pore. Biochim. Biophys. Acta 2008, 1777(7-8):946-952.
96. Levy M., Faas G.C., Saggau P., Craigen W.J., Sweatt J.D. Mitochondrial regulation of synaptic plasticity in the hippocampus. J. Biol. Chem. 2003, 278(20):17727-17734.
97. Li X., Sundquist J., Sundquist K. Age-specific familial risks of psychotic disorders and schizophrenia: a nation-wide epidemiological study from Sweden. Schizophr. Res. 2007, 97:43-50.
98. Li Z., Okamoto K., Hayashi Y., Sheng M. The importance of dendritic mitochondria in the morphogenesis and plasticity of spines and synapses. Cell 2004, 119:873-887.
99. Lieberman J.A. Is schizophrenia a neurodegenerative disorder? A clinical and neurobiological perspective. Biol. Psychiatry 1999, 46(6):729-739.
100. Liu J., Wang X., Shigenaga M.K., Yeo H.C., Mori A., Ames B.N. Immobilization stress causes oxidative damage to lipid, protein, and DNA in the brain of rats. FASEB J. 1996, 10:1532-1538.
101. Looney J., Childs H. The lactic acid and glutathione content of the blood of schizophrenic patients. J. Clin. Invest. 1934, 13:963-968.
102. López-Armada M.J., Riveiro-Naveira R.R., Vaamonde-García C., Valcárcel-Ares M.N. Mitochondrial dysfunction and the inflammatory response?. Mitochondrion 2013, 13(2):106-118.
103. Lu B. Mitochondrial dynamics and Neurodegeneration. Curr. Neurol. Neurosci. Rep. 2009, 9:212-219.
104. MacAskill A.F., Brickley K., Stephenson F.A., Kittler J.T. GTPase dependent recruitment of Grif-1 by Miro1 regulates mitochondrial trafficking in hippocampal neurons. Mol. Cell. Neurosci. 2009, 40:301-312.
105. Magri C., Gardella R., Barlati S.D., Valsecchi P., Sacchetti E., Barlati S. Mitochondrial DNA haplogroups and age at onset of schizophrenia. Am. J. Med Genet. 2007, 144B:496-501.
106. Mao Y., Ge X., Frank C.L., Madison J.M., Angela N., Doud M.K., et al. DISC1 regulates neural progenitor proliferation via modulation of GSK3β/β-catenin signaling. Cell 2009, 136:1017-1031.
107. Marchbanks R.M., Ryan M., Day I.N.M., Owen M., McGuffin P., Whatley S.A. A mitochondrial DNA sequence variant associated with schizophrenia and oxidative stress. Schizophr. Res. 2003, 65:33-38.
108. Marí M., Morales A., Colell A., García-Ruiz C., Fernández-Checa J.C. Mitochondrial glutathione, a key survival antioxidant. Antioxid. Redox Signaling 2009, 11(11):2685-2700.
109. Martínez-Cengotitabengoa M., Mac-Dowell K.S., Leza J.C., Micó J.A., Fernandez M., Echevarría E., Sanjuan J., Elorza J., González-Pinto A. Cognitive impairment is related to oxidative stress and chemokine levels in first psychotic episodes. Schizophr. Res. 2012, 137:66-72.
110. Martins-de-Souza D., Gattaz W.F., Schmitt A., Novello J.C., Marangoni S., Turck C.W., Dias-Neto E. Proteome analysis of schizophrenia patients Wernicke's area reveals an energy metabolism dysregulation. BMC Psychiatry 2009, 30(9):17.
111. Martins-de-Souza D., Maccarrone G., Wobrock T., Zerr I., Gormanns P., Reckow S., Falkai P., Schmitt A., Turck C.W. Proteome analysis of the thalamus and cerebrospinal fluid reveals glycolysis dysfunction and potential biomarkers candidates for schizophrenia. J. Psychiatr. Res. 2010, 44:1176-1189.
112. 1H-MRS studies. Schizophr. Bull. 2013, 39(1):120-129.
113. Martorell L., Segués T., Folch G., Valero J., Joven J., Labad A., et al. New variants in the mitochondrial genomes of schizophrenic patients. Eur. J. Hum. Genet.: EJHG 2006, 14:520-528.
114. Masserano J.M., Gong L., Kulaga H., Baker I., Wyatt R.J. Dopamine induces apoptotic cell death of a catecholaminergic cell line derived from the central nervous system. Mol. Pharmacol. 1996, 50:1309-1315.
115. Mattson M.P., Partin J. Evidence for mitochondrial control of neuronal polarity. J. Neurosci. Res. 1999, 56:8-20.
116. Mattson M.P., Gleichmann M., Cheng A. Mitochondria in neuroplasticity and neurological disorders. Neuron 2008, 60:748-766.
117. Maurer I., Zierz S., Möller H. Evidence for a mitochondrial oxidative phosphorylation defect in brains from patients with schizophrenia. Schizophr. Res. 2001, 48:125-136.
118. McGlashan T.H. The Chestnut Lodge follow-up study. II. Long-term outcome of schizophrenia and the affective disorders. Arch. Gen. Psychiatry 1984, 41:586-601.
119. McGlashan T.H., Hoffman R.E. Schizophrenia as a disorder of developmentally reduced synaptic connectivity?. Arch. Gen. Psychiatry 2000, 57(7):637-648.
120. Medler K., Gleason E.L. Mitochondrial Ca(2+) buffering regulates synaptic transmission between retinal amacrine cells. J. Neurophysiol. 2002, 87:1426-1439.
121. Meyer J.N., Leung M.C., Rooney J.P., Sendoel A., Hengartner M.O., Kisby G.E., Bess A.S. Mitochondria as a target of environmental toxicants?. Toxicol. Sci. 2013, 134(1):1-17.
122. Meyer U. Developmental neuroinflammation and schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 2013, 5(42):20-34.
123. Millar J.K., James R., Christie S., Porteous D.J. Disrupted in schizophrenia 1 (DISC1): subcellular targeting and induction of ring mitochondria. Mol. Cell. Neurosci. 2005, 30(4):477-484.
124. Modica-Napolitano J.S., Lagace C.J., Brennan W.A., Aprille J.R. Differential effects of typical and atypical neuroleptics on mitochondrial function in vitro. Arch. Pharm. Res. 2003, 26:951-959.
125. Moghaddam B., Javitt D. From the revolution to evolution: the glutamate hypothesis of schizophrenia and its impliication for treatment. Neuropsychopharmacology 2012, 37(1):4-15.
126. Möller M., Du Preez J.L., Viljoen F.P., Berk M., Harvey B.H. N-acetyl cysteine reverses social isolation rearing induced changes in cortico-striatal monoamines in rats. Metab. Brain Dis. 2013, 28(4):687-696.
127. Mosquera-Miguel A., Torrell H., Abasolo N., Arrojo M., Paz E., Ramos-Ríos R., Agra S., Páramo M., Brenlla J., Martínez S., Vilella E., Valero J., Gutiérrez-Zotes A., Martorell L., Costas J., Salas A. No evidence that major mtDNA European haplogroups confer risk to schizophrenia. Am. J. Med. Genet. 2012, 59B(4):414-421.
128. Moylan S., Berk M., Dean O.M., Samuni Y., Williams L.J., O'Neil A., Hayley A.C., Pasco J.A., Anderson G., Jacka F.N., Maes M. Oxidative & nitrosative stress in depression: why so much stress?. Neurosci. Biobehav. Rev. 2014, 45:46-62.
129. Munakata K., Iwamoto K., Bundo M., Kato T. Mitochondrial DNA 3243A>G mutation and increased expression of LARS2 gene in the brains of patients with bipolar disorder and schizophrenia. Biol. Psychiatry 2005, 57(5):525-532.
130. Murphy M.P. Mitochondrial thiols in antioxidant protection and redox signaling: distinct roles for glutathionylation and other thiol modifications. Antioxid. Redox Signaling 2012, 16(6):476-495. 15.
131. Naik E., Dixit V.M. Mitochondrial reactive oxygen species drive proinflammatory cytokine production. J. Exp. Med. 2011, 208:417-420.
132. Nicholls D., Akerman K. Mitochondrial calcium transport. Biochim. Biophys. Acta 1982, 683:57-88.
133. Nicholls D.G. A role for the mitochondrion in the protection of cells against calcium overload?. Prog. Brain Res. 1985, 63:97-106.
134. Nicholls D.G., Budd S.L. Mitochondria and neuronal survival. Physiol. Rev. 2000, 80:315-360.
135. Nicholls D.G. Mitochondrial calcium function and dysfunction in the central nervous system. Biochim. Biophys. Acta 2009, 1787:1416-1424.
136. O'Donnell P., Do K.Q., Arango C. Oxidative/Nitrosative Stress in Psychiatric Disorders: Are We There Yet?. Schizophr Bull 2014, 40(5):960-962.
137. Olabi B., Ellison-Wright I., McIntosh A.M., Wood S.J., Bullmore E., Lawrie S.M. Are there progressive brain changes in schizophrenia? A meta-analysis of structural magnetic resonance imaging studies. Biol. Psychiatry 2011, 70(1):88-96.
138. Otte D.M., Sommersberg B., Kudin A., Guerrero C., Albayram O., Filiou M.D., Frisch P., Yilmaz O., Drews E., Turck C.W., Bilkei-Gorzó A., Kunz W.S., Beck H., Zimmer A. N-acetyl cysteine treatment rescues cognitive deficits induced by mitochondrial dysfunction in G72/G30 transgenic mice?. Neuropsychopharmacology 2011, 36(11):2233-2243.
139. Park Y.U., Jeong J., Lee H., Mun J.Y., Kim J.H., Lee J.S., et al. Disrupted-in-schizophrenia 1 (DISC1) plays essential roles in mitochondria in collaboration with Mitofilin. Proc. Natl. Acad. Sci. U.S.A. 2010, 107(41):17785-17790.
140. Park C., Park S.K. Molecular links between mitochondrial dysfunctions and schizophrenia. Mol. Cells 2012, 33(2):105-110.
141. Patel S.P., Sullivan P.G., Pandya J.D., Goldstein G.A., Vanrooyen J.L., Yonutas H.M., Eldahan K.C., Morehouse J., Magnuson D.S., Rabchevsky A.G. N-acetylcysteine amide preserves mitochondrial bioenergetics and improves functional recovery following spinal trauma. Exp Neurol. 2014, 257:95-105.
142. Pedrini M., Massuda R., Fries G.R., de Bittencourt Pasquali M.A., Schnorr C.E., Moreira J.C., Teixeira A.L., Lobato M.I., Walz J.C., Belmonte-de-Abreu P.S., Kauer-Sant'Anna M., Kapczinski F., Gama C.S. Similarities in serum oxidative stress markers and inflammatory cytokines in patients with overtschizophrenia at early and late stages of chronicity?. J. Psychiatr. Res. 2012, 46(6):819-824.
143. Pereira S.L., Grãos M., Rodrigues A.S., Anjo S.I., Carvalho R.A., et al. Inhibition of mitochondrial complex III blocks neuronal differentiation and maintains embryonic stem cell pluripotency. PLoS One 2013, 8(12):e82095.
144. Pérez-Neri I., Ramírez-Bermúdez J., Montes S., Ríos C. Possible mechanisms of neurodegeneration in schizophrenia?. Neurochem. Res. 2006, 31(10):1279-1294.
145. Picard M., McEwen B.S. Mitochondria impact brain function and cognition. Proc. Natl. Acad. Sci. U.S.A. 2014, 111(1):7-8.
146. Pivovarova N.B., Andrews S.B. Calcium-dependent mitochondrial function and dysfunction in neurons. FEBS J. 2010, 277(18):3622-3636.
147. Prabakaran S., Swatton J.E., Ryan M.M., Huffaker S.J., Huang J.T.-J., Griffin J.L., et al. Mitochondrial dysfunction in schizophrenia: evidence for compromised brain metabolism and oxidative stress. Mol. Psychiatry 2004, 9(7):684-697. 643.
148. Prince J.A., Blennow K., Gottfries C.G., Karlsson I., Oreland L. Mitochondrial function is differentially altered in the basal ganglia of chronic schizophrenics. Neuropsychopharmacology 1999, 21(3):372-379.
149. Puri B.K. Progressive structural brain changes in schizophrenia. Expert Rev. Neurotherap. 2010, 10(1):33-42.
150. Rabilloud T., Heller M., Rigobello M.P., Bindoli A., Aebersold R., Lunardi J. The mitochondrial antioxidant defence system and its response to oxidative stress?. Proteomics 2001, 1(9):1105-1110.
151. Raffa M., Mechri A., Othman L., Ben Fendri C., Gaha L., Kerkeni A. Decreased glutathione levels and antioxidant enzyme activities in untreated and treated schizophrenic patients. Prog. Neuropsychopharmacol. Biol. Psychiat. 2009, 33(7):1178-1183.
152. Regenold W.T., Phatak P., Marano C.M., Sassan A., Conley R.R., Kling M.A. Elevated cerebrospinal fl{ligature}uid lactate concentrations in patients with bipolar disorder and schizophrenia: implications for the mitochondrial dysfunction hypothesis. Biol. Psychiatr. 2009, 65:489e94.
153. Regenold W.T., Pratt M., Nekkalapu S., Shapiro P.S., Kristian T., Fiskum G. Mitochondrial detachment of hexokinase 1 in mood and psychotic disorders: implications for brain energy metabolism and neurotrophic signaling. J. Psychiatr. Res. 2012, 46(1):95-104.
154. Robicsek O., Karry R., Petit I., Salman-Kesner N., Müller F.-J., Klein E., et al. Abnormal neuronal differentiation and mitochondrial dysfunction in hair follicle-derived induced pluripotent stem cells of schizophrenia patients. Mol. Psychiatry 2013, 18(10):1067-1076.
155. Rollins B., Martin M.V., Sequeira P.A., Moon E.a., Morgan L.Z., Watson S.J., et al. Mitochondrial variants in schizophrenia, bipolar disorder, and major depressive disorder. PLoS One 2009, 4(3):e4913.
156. Rosenfeld M., Brenner-Lavie H., Ari S.G.-B., Kavushansky A., Ben-Shachar D. Perturbation in mitochondrial network dynamics and in complex I dependent cellular respiration in schizophrenia. Biol. Psychiatry 2011, 69(10):980-988.
157. Schon E.A., Manfredi G. Neuronal degeneration and mitochondrial dysfunction?. J Clin Invest. 2003, 111(3):303-312.
158. Sequeira A., Martin M.V., Rollins B., Moon E.A., Bunney W.E., Macciardi F., Lupoli S., Smith E.N., Kelsoe J., Magnan C.N., van Oven M., Baldi P., Wallace D.C., Vawter M.P. Mitochondrial mutations and polymorphisms in psychiatric disorders. Front. Genet. 2012, 20(3):103.
159. Sharpley M.S., et al. Heteroplasmy of mouse mtDNA is genetically unstable and results in altered behavior and cognition. Cell 2012, 151(2):333-343.
160. Shimizu A., Kurachi M., Yamaguchi N., Torii H., Isaki K. Morbidity risk of schizophrenia to parents and siblings of schizophrenic patients. Jpn. J. Psychiatry Neurol. 1987, 41:65-71.
161. Singh O.P., Chakraborty I., Datta S. A comparative study of oxidative stress and interrelationship of important antioxidants in haloperidol and olanzapine treated patients suffering from schizophrenia. Indian J. Psychiatry 2008, 50(3):1-8.
162. Smaili S.S., Ureshino R.P., Rodrigues L., Rocha K.K., Carvalho J.T., Oseki K.T., Bincoletto C., Lopes G.S., Hirata H. The role of mitochondrial function in glutamate-dependent metabolism in neuronal cells. Curr. Pharm. Des. 2011, 17(35):3865-3877.
163. Somerville S.M., Conley R.R., Roberts R.C. Mitochondria in the striatum of subjects with schizophrenia. World J. Biol. Psychiatry 2011, 12(1):48-56.
164. Starkov A.A., Chinopoulos C., Fiskum G. Mitochondrial calcium and oxidative stress as mediators of ischemic brain injury. Cell Calcium 2004, 36:257-264.
165. Stavrovskaya I.G., Kristal B.S. The powerhouse takes control of the call: is the mitochondrial permeability transition a viable therapeutic target against neuronal dysfunction and death?. Free Radical Biol. Med. 2005, 38(6):687-697.
166. Stork C., Renshaw P.F. Mitochondrial dysfunction in bipolar disorder: evidence from magnetic resonance spectroscopy research. Mol. Psychiatry 2005, 10:900-919.
167. Saha S., Chant D., Welham J., McGrath J. A systematic review of the prevalence of schizophrenia. PLoS Med. 2005, 2(5):e141.
168. Tang Y., Zucker R.S. Mitochondrial involvement in post-tetanic potentiation of synaptic transmission. Neuron 1997, 18:483-491.
169. Tsai M.C., Liou C.W., Lin T.K., Lin I.M., Huang T.L. Changes in oxidative stress markers in patients with schizophrenia: the effect of antipsychotic drugs. Psychiatry Res. 2013, 209(3):284-290.
170. Ueno H., Nishigaki Y., Kong Q.P., Fuku N., Kojima S., Iwata N., et al. Analysis of mitochondrial DNA vriants in Japanese patients with schizophrenia. Mitochondrion 2009, 9:385-393.
171. Uranova N., Orlovskaya D., Vikhreva O., Zimina I., Kolomeets N., Vostrikov V., et al. Electron microscopy of oligodendroglia in severe mental illness. Brain Res. Bull. 2001, 55:597-610.
172. Uranova, N., Bonartsev, P., Brusov, O., Morozova, M., Rachmanova, V., Orlovskaya, D., 2007. The ultrastructure of lymphocytes in schizophrenia. World J. Biol. Psychiatry. 8, 30-37.
173. Van Os J., Kapur S. Schizophrenia. Lancet 2009, 374(9690):635-645.
174. Vayssiere J.L., Cordeau-Lossouarn L., Larcher J.C., Basseville M., Gros F., Croizat B. Participation of the mitochondrial genome in the differentiation of neuroblastoma cells. In Vitro Cell Dev. Biol. 1992, 28A(11-12):763-772.
175. Velarde M.C. Pleiotropic actions of estrogen: a mitochondrial matter. Physiol. Genomics 2013, 45(3):106-109.
176. Venkatasubramanian G., Debnath M. The TRIPS (Toll-like receptors in immuno-inflammatory pathogenesis) hypothesis: a novel postulate to understand schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiat. 2013, 44:301-311.
177. Verge B., Alonso Y., Valero J., Miralles C., Vilella E., Martorell L. Mitochondrial DNA (mtDNA) and schizophrenia. Eur. Psychiatry 2011, 26(1):45-56.
178. Verge B., Alonso Y., Miralles C., Valero J., Vilella E., Boles R.G., Martorell L. New evidence for the involvement of mitochondrial inheritance in schizophrenia: results from a cross-sectional study evaluating the risk of illness in relatives of schizophrenia patients?. J. Clin. Psychiatry 2012, 73(5):684-690.
179. Vita A., De Peri L., Deste G., Sacchetti E. Progressive loss of cortical gray matter in schizophrenia: a meta-analysis and meta-regression of longitudinal MRI studies. Transl. Psychiatry 2012, 2(11):e190.
180. Voloboueva L.A., Lee S.W., Emery J.F., Palmer T.D., Giffard R.G. Mitochondrial protection attenuates inflammation-induced impairment of neurogenesis in vitro and in vivo. J. Neurosci. 2010, 30(37):12242-12251.
181. 31P chemical shift spectroscopic-imaging study. Biol. Psychiatry 2000, 41:954-961.
182. Van Haren N.E.M., Hulshoff Pol H.E., Schnack H.G., et al. Progressive brain volume loss in schizophrenia over the course of the illness: evidence of maturational abnormalities in early adulthood. Biol. Psychiatry 2008, 63:106-113.
183. Wagner K.R., Kleinholz M., Myers R.E. Delayed decreases in specific brain mitochondrial electron transfer complex activities and cytochrome concentrations following anoxia/ischemia?. J. Neurol. Sci. 1990, 100(1-2):142-151.
184. Wang G., Zhang Y., Zhang Y., Dong Y., Lv Z., Sun M., et al. Mitochondrial haplogroups and hypervariable region polymorphisms in schizophrenia: a case-control study. Psychiatry Res. 2013, 209(3):279-283.
185. Wells P.G., McCallum G.P., Chen C.S., Henderson J.T., Lee C.J.J., Perstin J., et al. Oxidative stress in developmental origins of disease: teratogenesis, neurodevelopmental deficits, and cancer. Toxicol. Sci. 2009, 108(1):4-18.
186. J.E. Wilson, 2003, Isozymes of mammalian hexokinase: structure, subcellular localization and metabolic function, The Journal of Experimental Biology, 206, 2049-2057.
187. Wilson T.J., Slupe A.M., Strack S. Cell signaling and mitochondrial dynamics: implications for neuronal function and neurodegenerative disease. Neurobiol. Dis. 2013, 51:13-26.
188. Wood S.J., Yücel M., Pantelis C., Berk M. Neurobiology of schizophrenia spectrum disorders: the role of oxidative stress?. Ann. Acad. Med. Singapore 2009, 38(5):396-406.
189. Yao J., Brinton R.D. Estrogen regulation of mitochondrial bioenergetics: implications for prevention of Alzheimer's disease. Adv. Pharmacol. 2012, 64:327-371.
190. Zhang L., Yang H., Zhao H., Zhao C. Calcium-related signaling pathways contributed to dopamine-induced cortical neuron apoptosis. Neurochem. Int. 2011, 58:281-294.
191. Zhang W., Tang J., Zhang A.-M., Peng M.-S., Xie H.-B., Tan L., Xu L., Zhang Y.-P., Chen X., Yao Y.-G. A matrilineal genetic legacy from the Last Glacial Maximum confers susceptibility to schizophrenia in Han Chinese. J. Genet. Genomics 2014, 41(7):397-407.
192. Zhao N., Zhong C., Wang Y., Zhao Y., Gong N., Zhou G., Xu T., Hong Z. Impaired hippocampal neurogenesis is involved in cognitive dysfunction induced by thiamine deficiency at early pre-pathological lesion stage. Neurobiol. Dis. 2008, 29:176-185.
193. Zucker R.S. Short-term synaptic plasticity. Annu. Rev. Neurosci. 1989, 12:13-31.